Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Abstract

In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

Keywords

GemcitabineMedicineInternal medicinePancreatic cancerHazard ratioPaclitaxelDeoxycytidineOncologyClinical endpointChemotherapyPerformance statusGastroenterologyCancerConfidence intervalClinical trial

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Publication Info

Year: 2013
Type: article
Volume: 369
Issue: 18
Pages: 1691-1703
Citations: 6383
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

6383

OpenAlex

Cite This

APA Style

                            
                                
                                    Daniel D. Von Hoff, 
                                
                                    Thomas J. Ervin, 
                                
                                    Francis P. Arena
                                
                                et al.
                            
                            (2013). 
                            Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. 
                            New England Journal of Medicine
                            , 369
                            (18)
                            , 1691-1703.
                            https://doi.org/10.1056/nejmoa1304369
                        

Identifiers

DOI: 10.1056/nejmoa1304369